Abstract | BACKGROUND/AIM: MATERIALS AND METHODS: AHCC was applied to KLM1-R cells and expression of SOX2 was analyzed by western blotting. RESULTS: AHCC down-regulated SOX2 in KLM1-R cells. Nanog and Oct4, co-workers of SOX2 in maintaining pluripotency, did not exhibit any significant change in protein expression. CONCLUSION: We showed the potential of AHCC to be a candidate for combinatorial therapy in anticancer drug regimens. This result suggests that the target of AHCC in expressing therapeutic efficacy was not the pluripotent cells such as cancer stem cells (CSCs) but SOX2-specific.
|
Authors | Junya Nawata, Yasuhiro Kuramitsu, Yufeng Wang, Takao Kitagawa, Kazuhiro Tokuda, Byron Baron, Junko Akada, Shigeyuki Suenaga, Seiji Kaino, Shin-Ichiro Maehara, Yoshihiko Maehara, Isao Sakaida, Kazuyuki Nakamura |
Journal | Anticancer research
(Anticancer Res)
Vol. 34
Issue 9
Pg. 4807-11
(Sep 2014)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 25202061
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. |
Chemical References |
- Actins
- Polysaccharides
- SOX2 protein, human
- SOXB1 Transcription Factors
- Active Hexose Correlated Compound
|
Topics |
- Actins
(metabolism)
- Cell Line, Tumor
- Gene Expression Regulation, Neoplastic
(drug effects)
- Humans
- Neoplastic Stem Cells
(metabolism)
- Pancreatic Neoplasms
(genetics, metabolism)
- Polysaccharides
(pharmacology)
- SOXB1 Transcription Factors
(genetics, metabolism)
|